Insulin and reconciliation

With Congress sending to the president a partisan reconciliation spending bill, the cost of insulin is receiving greater attention. Numerous proposals have been introduced in recent months aimed at...
Read More
Ask About Adherence: 3 factors impacting medication adherence for patients with diabetes and how our proactive affordability solutions can help

Earlier this year, PhRMA released a proactive agenda with common-sense, patient-centered reforms to improve access to quality, affordable health care. The urgency of building a stronger, more...
Read More
New insulin report highlights how incentives benefit middlemen, harm patients

The Senate Finance Committee has released a new report detailing findings of their investigation into the role that market dynamics play in the pricing of insulins. The report conclusions further...
Read More
Sharing rebates can improve access to medicines and increase health equity

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Guest post: H.R.3 is the wrong approach to help patients like me

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Guest post: Sharing discounts and rebates is the right thing to do

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
New report shows more than 160 medicines in development for diabetes and related conditions

Diabetes represents a significant public health issue in the U.S. It affects more than 30 million Americans, including around 7.2 million who are undiagnosed. Additionally, there are close to 1.5...
Read More
Five key facts about the market for insulins

A century ago, patients were treated with animal insulins. Today, biopharmaceutical companies produce insulins that operate at the molecular level, more closely resembling insulin released naturally...
Read More
Six key facts about the market for insulins

The insulin market is commonly mischaracterized as lacking competition. In fact, robust competition among biopharmaceutical companies that produce insulin results in increasing levels of discounts...
Read More
Ask About Adherence: New study finds one-third of newly diagnosed diabetic patients aren’t starting treatment

Ask About Adherence is a blog series featuring Q&A’s with experts and new medication adherence resources. In this post, we are pleased to share a blog post from Lauren Gilstrap, MD, MPH. ...
Read More